TG Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel therapeutics for B-cell related diseases including autoimmune diseases
Company stage: Clinical
Diseases: B-cell related autoimmune diseases including multiple sclerosis
Genome-editing tool: Meganucleases
Funding stage: Post-IPO Debt
Location: New York City, New York, USA
Website: https://www.tgtherapeutics.com/
Pipeline: https://www.tgtherapeutics.com/our-pipeline/overview-pipeline/
Partners: Precision BioSciences
TG Therapeutics is a biopharmaceutical company focused on developing novel treatments for B-cell diseases, including various forms of cancer and autoimmune diseases. Their primary disease focus is on autoimmune diseases, especially multiple sclerosis (MS). The company's pipeline includes Phase 3 and approved monoclonal antibody treatments for MS, as well as an investigational trial for MS with Azer-Cel, a clinical-stage therapeutic candidate comprising gene-edited donor-derived T cells.